ABOUT
An independent digest of the BPC-157 TB-500 record
We read two peptide literatures and one regulatory record, and we lay them out cell by cell. We are an editorial publisher — not a clinic, not a telehealth service, not a vendor.
What this site is
Wolverine Telehealth is an independent editorial project that publishes summaries of the peer-reviewed research literature on BPC-157 TB-500 — the two-peptide blend pairing BPC-157 with the Thymosin Beta-4 fragment TB-500. We are not a clinic. We do not employ clinicians, and we do not provide medical advice. We do not manufacture, sell, or distribute any product. Our work is editorial commentary on publicly available science and on the public regulatory record.
The site is organized as a bento board on purpose. The Wolverine blend is two distinct peptides, each with its own mechanism and its own literature, joined by a synergy that has never been tested. A mosaic of cells is the honest way to show that: each constituent gets its own panel, the shared repair rationale gets its own, and the gaps — no controlled combination study, no validated blend dose, both components in FDA 503A Category 2 — get their own deliberate cells rather than being smoothed over.
On the word 'telehealth' in our name
The 'telehealth' in this domain is editorial framing — the position this publisher takes relative to the medicinal-access conversation around peptides — not a claim about services we offer. We do not run telehealth consultations, we do not connect readers to prescribers, and we do not facilitate access to any substance. We summarize how the regulatory landscape works in general terms, and we cite the FDA record directly.
When we describe the lawful compounded-access pathway on the Wolverine legal status and FDA 503A category page, we do so as general information about the framework, naming no pharmacy, clinic, telehealth provider, or vendor. That page exists because readers ask whether the blend is legal and how access works; answering accurately is editorial service, not medical or legal advice.
How we handle evidence
Every quantitative claim on this site is attributed to a specific study, listed in the full reference list. Where a finding belongs to one component, we say so; where it was generated with full-length Thymosin Beta-4 rather than the TB-500 heptapeptide, we flag the distinction. Where the blend itself has no data — which is most places a person would expect data — we say that plainly rather than borrowing a component result to fill the gap.
We describe doses as they were administered in animal studies, never as human instructions. We do not recommend protocols. The aim is a digest a careful reader can verify line by line against the sources, and a record that stays honest about what two separately studied peptides do and do not jointly demonstrate.